Merck's HIV Bet: Once-Weekly Breakthrough and a Bigger Monthly PrEP Opportunity

AIDS 2026 sharpened the case for Merck's wider HIV pipeline

Merck's HIV story looked broader at AIDS 2026 than it did after the recent FDA approval of IDVYNSO. The company used the conference to showcase one of the industry's broadest HIV innovation pipelines, with daily, weekly and monthly options across treatment and prevention.

That matters because Merck is no longer leaning on a single launch. It is laying out a more continuous set of options: a newly approved therapy, once-weekly investigational treatment data, and a once-monthly PrEP candidate still in Phase 3. For investors, that is the difference between a one-product headline and a more durable franchise.

Once-weekly treatment is the near-term proof point

The clearest near-term win is islatravir/lenacapavir. In the Phase 3 ISLEND-1 and ISLEND-2 studies, the regimen met the Week 48 primary efficacy endpoint in virologically suppressed adults switching from BIKTARVY or other standard regimens. That is the core signal: the weekly oral approach has moved from concept to proof-of-concept.

The commercial angle follows from the clinical one. If a less frequent regimen helps people stay on therapy with less friction, Merck is competing on convenience as well as efficacy. The regimen also has the potential to be the first approved long-acting oral HIV treatment taken once-weekly, which could help it stand out if approved.

Once-monthly PrEP remains the larger upside

The bigger franchise question sits in prevention. Merck is advancing alimatravir as a once-monthly oral pill as pre-exposure prophylaxis (PrEP) for the prevention of HIV-1 while Phase 3 trials continue. If that program succeeds, Merck would add a convenience-led prevention option to a portfolio that already includes treatment candidates with different dosing schedules.

This is also where access strategy matters. Merck said its early access plan for alimatravir includes Voluntary licensing agreements cover 129 countries in regions which account for the substantial majority of new HIV diagnoses globally. That does not guarantee a strong return profile, but it does show Merck is thinking about scale early rather than waiting for approval to start planning distribution.

Where the bull and bear cases diverge

The bull case is that Merck is building a ladder of options rather than betting everything on one product. Weekly treatment could win first on convenience and adherence. Monthly PrEP could then broaden the franchise if the Phase 3 data hold up.

The bear case is that convenience does not automatically translate into attractive economics. The access plans most relevant to global volume are tied to voluntary licensing, and those agreements often come with lower pricing than investors may be accustomed to in the U.S. market. Conference-stage announcements also say less than commercial execution. On top of that, daily, once-weekly, and once-monthly HIV options are already part of the competitive conversation, so Merck still has to prove it can earn meaningful share.

What would strengthen the thesis next

The next important checks are practical:

• Whether the weekly treatment data continue to support a clean efficacy and safety profile in regulatory filings.
• Whether alimatravir's Phase 3 progress keeps the monthly PrEP opportunity alive.
• Whether Merck can turn early access planning into commercially credible execution.

For now, the cleanest way to read the story is this: treatment has the nearer proof point, while prevention still holds the larger long-term upside.